Moody’s Investors Service

Report: U.S. specialty pharma’s M&A focus shifts to pipelines and innovative products

Tuesday, June 14, 2016

Despite the ongoing challenges weighing on the U.S. specialty pharmaceutical sector, companies will steadily resume M&A with a more refined focus, said Moody’s Investors Service. The ratings agency said it expects acquisitive specialty companies will increase their focus on products with unmet medical need, companies with pipeline drugs and those providing geographic expansion.

[Read More]